Impact of a five-dimensional framework on R&D productivity at AstraZeneca¶
Morgan, P., Brown, D. G., & Lennard, S. (2018). Impact of a five-dimensional framework on R&D productivity at AstraZeneca. Nature Reviews Drug Discovery.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Domain-specific¶
- Riskiest Assumption Test
- The company subsequently reported a marked improvement in the proportion of projects surviving through the pipeline.
This sourceReports that AstraZeneca's success rates from candidate drug nomination to phase III completion rose from 4% in 2005-2010 to 19% in 2012-2016.
SupportedVerified against the work's full text
“success rates from candidate drug nomination to phase III completion improving from 4% in 2005–2010 to 19% in 2012–2016.”
- The company subsequently reported a marked improvement in the proportion of projects surviving through the pipeline.
Verification¶
Does it exist? Not checked yet. This work's DOI is recorded above but has not been resolved against an external catalogue, so nothing here confirms the work exists.
Does it back the claim? Read against the text for 1 of 1 citation: 1 supported. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:6e8eeaf1dcc6 · see in the full table